Document Detail


Energy expenditure and impact of bronchodilators in COPD patients.
MedLine Citation:
PMID:  20471237     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
28 Consecutive COPD patients performed four 6-minute walking tests (6-MWTs) in 2 different days before and 2, 4 and 6h after the inhalation of formoterol 12microg or tiotropium 18microg, respectively. Physical activity during each 6-MWT was assessed by the SenseWear Armband. At each time also spirometry was performed. Both formoterol and tiotropium induced a significantly sustained bronchodilation and influenced hyperinflation. Formoterol significantly increased distance walked in 6min at 2h and at 4h, whereas tiotropium significantly increased it at all time points. There was a trend to an increase in calories and metabolic equivalents of task (METs) after formoterol and a decrease after tiotropium, but changes were not statistically significant. Total energy expenditure for each 6-MWT was not changed by formoterol, but decreased in significant manner 6h after the inhalation of tiotropium. Active energy expenditure at physical activity level of more than 3 METs decreased significantly after tiotropium at each 6-MWT, but not after formoterol. We did not find any significant correlation between the changes in lung function and those of parameters recorded with SenseWear Armband. Our study seems to indicate that tiotropium, but not formoterol, is able to reduce energy expenditure in COPD patients, although both drugs elicit significant bronchodilation and are able to increase the distance walked in 6min.
Authors:
Mario Cazzola; Andrea Segreti; Emanuele Stirpe; Massimiliano Appodia; Lucia Senis; Maria G Matera
Related Documents :
10949867 - Prevalence, age distribution and aetiology of bronchiectasis: a retrospective study on ...
16236847 - Airway and systemic inflammation and decline in lung function in patients with copd.
16614347 - Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe a...
11868137 - Treatment of snoring and obstructive sleep apnea with a mandibular protruding device: a...
10836337 - Clearance of inhaled technetium-99m-dtpa as a clinical index of pulmonary vascular dise...
1277987 - Hyperpyrexia in catatonic states.
Publication Detail:
Type:  Journal Article     Date:  2010-05-14
Journal Detail:
Title:  Respiratory medicine     Volume:  104     ISSN:  1532-3064     ISO Abbreviation:  Respir Med     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-09-06     Completed Date:  2011-02-24     Revised Date:  2013-06-11    
Medline Journal Info:
Nlm Unique ID:  8908438     Medline TA:  Respir Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  1490-4     Citation Subset:  IM    
Affiliation:
Division of Respiratory Diseases, Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy. mario.cazzola@uniroma2.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Bronchodilator Agents / therapeutic use*
Drug Therapy, Combination
Energy Metabolism / drug effects*,  physiology
Ethanolamines / therapeutic use*
Exercise Test / methods
Exercise Tolerance / drug effects*,  physiology
Female
Forced Expiratory Volume / drug effects
Humans
Male
Middle Aged
Pulmonary Disease, Chronic Obstructive / drug therapy*,  physiopathology
Scopolamine Derivatives / therapeutic use*
Spirometry
Treatment Outcome
Walking / physiology
Chemical
Reg. No./Substance:
0/Bronchodilator Agents; 0/Ethanolamines; 0/Scopolamine Derivatives; 0EB439235F/tiotropium; 5ZZ84GCW8B/formoterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Determinants of poor 6-min walking distance in patients with COPD: The ECLIPSE cohort.
Next Document:  Assessing dyspnea and its impact on patients with connective tissue disease-related interstitial lun...